Registry update — unassessed
Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain: a Randomized, Double-blind, Placebo-controlled Trial
Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.
RCTMinor significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Oct 5, 2026 · Discovered: Oct 5, 2026 · Assessed: — · Research update
What it does not prove
- This is a protocol or background document, not a results report—no outcome data are presented.
- The efficacy or safety of semaglutide in this specific population and timing cannot be assessed from this abstract.
- Whether combining semaglutide with conversion surgery outperforms either intervention alone is not addressed in the material provided.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Patients with recurrent weight gain after sleeve gastrectomy (SG)
- Primary outcome
- Weight loss comparison between semaglutide and conversion of sleeve gastrectomy to Roux-en-Y gastric bypass
- Effect size
- —
- Significance
- Not reported
- Journal
- General Committee of Teaching Hospitals and Institutes, Egypt
- Published
- Oct 5, 2026
Sources
Primary source
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
Recurrent weight gain affects 15% to 40% of patients after metabolic and bariatric surgery (MBS). SG is the most performed operation worldwide, and long-term regain after SG is well documented.
Conversion of SG to RYGB gives around 20% additional total weight loss at 12 months across all indications
Semaglutide gives around 11% total weight loss
This protocol is that trial.
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.